Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 4, 2015, Pages 2337-2342

  De Jonge, Boudewijn L M ^a   Kutschke, Amy ^a   Newman, Joseph V ^a   Rooney, Michael T ^a   Yang, Wei ^a   Cederberg, Christer ^b  

^a ASTRAZENECA   (United Kingdom)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; BACTERIAL ENZYME; BETA CYCLODEXTRIN SULFOBUTYL ETHER; DIAZEPINE DERIVATIVE; GLUTAMATE RACEMASE; HYDROXYPROPYLMETHYLCELLULOSE; PEPTIDOGLYCAN; PYRIDODIAZEPINE AMINE; RACEMASE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; AZEPINE DERIVATIVE; ISOMERASE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL GROWTH; BACTERIAL VIABILITY; BROTH DILUTION; COLONY FORMING UNIT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; ENZYME INHIBITION; GROWTH INHIBITION; HELICOBACTER PYLORI; LIQUID CHROMATOGRAPHY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SINGLE DRUG DOSE; STOMACH FISTULA; STOMACH MUCOSA; TANDEM MASS SPECTROMETRY; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; KINETICS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; SPRAGUE DAWLEY RAT;

AMINO ACID ISOMERASES; AMOXICILLIN; ANIMALS; ANTI-BACTERIAL AGENTS; AZEPINES; FEMALE; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; KINETICS; MICE; MICROBIAL SENSITIVITY TESTS; PEPTIDOGLYCAN; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84928922813     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04410-14     Document Type: Article

References (33)

1. Suerbaum S, Michetti P. 2002. Medical progress: Helicobacter pylori infection. N Engl J Med 347:1175-1186. http://dx.doi.org/10.1056/NEJMra020542.
2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ. 2001. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345:784-789. http://dx.doi.org/10.1056/NEJMoa001999.
3. Kamangar F, Dawsey SM, Blaser MJ, Perez-Perez GI, Pietinen P, Newschaffer CJ, Abnet CC, Albanes D, Virtamo J, Taylor PR. 2006. Opposing risks of gastric cardia and noncardia gastric adenocarcinomas associated with Helicobacter pylori seropositivity. J Natl Cancer Inst 98: 1445-1452. http://dx.doi.org/10.1093/jnci/djj393.
4. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ, European Helicobacter Study Group. 2012. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 61:646-664. http://dx.doi.org/10.1136/gutjnl-2012-302084.
5. Graham DY, Shiotani A. 2012. Which therapy for Helicobacter pylori infection? Gastroenterology 143:10-12. http://dx.doi.org/10.1053/j.gastro.2012.05.012.
6. Fischbach L, Evans EL. 2007. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 26:343-357. http://dx.doi.org/10.1111/j.1365-2036.2007.03386.x.
7. John P, O'Connor A, Taneike I, O'Morain C. 2009. Improving compliance with Helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol 2:273-279. http://dx.doi.org/10.1177/1756283X09337342.
8. Mégraud F. 2004. H. pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 53:1374-1384. http://dx.doi.org/10.1136/gut.2003.022111.
9. Lundqvist T, Fisher SL, Kern G, Folmer RHA, Xue Y, Newton DT, Keating TA, Alm RA, de Jonge BLM. 2007. Exploitation of structural and regulatory diversity in glutamate racemases. Nature 447:817-822. http://dx.doi.org/10.1038/nature05689.
10. Fisher SL. 2008. Glutamate racemase as a target for drug discovery. Microb Biotechnol 1:345-360. http://dx.doi.org/10.1111/j.1751-7915.2008.00031.x.
11. Turner RD, Vollmer W, Foster SJ. 2014. Different walls for rods and balls: the diversity of peptidoglycan. Mol Microbiol 91:862-874. http://dx.doi.org/10.1111/mmi.12513.
12. de Jonge BLM, Kutschke A, Uria-Nickelsen M, Kamp HD, Mills SD. 2009. Pyrazolopyrimidinediones are selective agents for Helicobacter pylori that suppress growth through inhibition of glutamate racemase (MurI). Antimicrob Agents Chemother 53:3331-3336. http://dx.doi.org/10.1128/AAC.00226-09.
13. Basarab GS, Hill PJ, Rastagar A, Webborn PJH. 2008. Design of Helicobacter pylori glutamate racemase inhibitors as selective antibacterial agents: a novel pro-drug approach to increase exposure. Bioorg Med Chem Lett 18:4716-4722. http://dx.doi.org/10.1016/j.bmcl.2008.06.092.
14. Geng B, Basarab G, Comita-Prevoir J, Gowravaram M, Hill P, Kiely A, Loch J, MacPherson L, Morningstar M, Mullen G, Osimboni E, Satz A, Eyermann C, Lundqvist T. 2009. Potent and selective inhibitors of Helicobacter pylori glutamate racemase (MurI): pyridodiazepine amines. Bioorg Med Chem Lett 19:930-936. http://dx.doi.org/10.1016/j.bmcl.2008.11.113.
15. de Jonge BLM, Kutschke A. 2006. abstr. F2-1174. 46th Intersci Conf Antimicrob Agents Chemother, 17 to 21 September 2006, San Francisco, CA.
16. Newman JV, Rooney MT, Cederberg C. 2006. abstr. A2-1106. 46th Intersci Conf Antimicrob Agents Chemother, 17 to 21 September 2006, San Francisco, CA.
17. Kutschke A, de Jonge BLM. 2005. Compound efflux in Helicobacter pylori. Antimicrob Agents Chemother 49:3009-3010. http://dx.doi.org/10.1128/AAC.49.7.3009-3010.2005.
18. Lee A, O'Rourke J, De Ungria JC, Robertson B, Daskalopoulos G, Dixon MF. 1997. A standardized mouse model of Helicobacter pylori infection: introducing the Sydney strain. Gastroenterology 112:1386-1397. http://dx.doi.org/10.1016/S0016-5085(97)70155-0.
19. Keating TA, Newman JV, Olivier NB, Otterson LG, Andrews B, Boriack-Sjodin PA, Breen JN, Doig P, Dumas J, Gangl E, Green OM, Guler SY, Hentemann MF, Joseph-McCarthy D, Kawatkar S, Kutschke A, Loch JT, McKenzie AR, Pradeepan S, Prasad S, Martínez-Botella G. 2012. In vivo validation of thymidylate kinase (TMK) with a rationallydesigned, selective antibacterial compound. ACS Chem Biol 7:1866-1872. http://dx.doi.org/10.1021/cb300316n.
20. Balani SK, Li P, Nguyen J, Cardoza K, Zeng H, Mu D-X, Wu J-T, Gan L-S, Lee FW. 2004. Effective dosing regimen of 1-aminobenzotriazole for inhibition of antipyrine clearance in guinea pigs and mice using serial sampling. Drug Metab Dispos 32:1092-1095. http://dx.doi.org/10.1124/dmd.104.000349.
21. Hassan I, Stark RM, Greenman J, Millar MR. 1999. Activities of-lactams and macrolides against Helicobacter pylori. Antimicrob Agents Chemother 43:1387-1392.
22. Irie Y, Tateda K, Matsumoto T, Miyazaki S, Yamaguchi K. 1997. Antibiotic MICs and short time-killing against Helicobacter pylori: therapeutic potential of kanamycin. J Antimicrob Chemother 40:235-240. http://dx.doi.org/10.1093/jac/40.2.235.
23. DeLoney CR, Schiller NL. 1999. Competition of various β-lactam antibiotics for the major penicillin-binding proteins of Helicobacter pylori: antibacterial activity and effects on bacterial morphology. Antimicrob Agents Chemother 43:2702-2709.
24. Keating TA. 2013. Resistance mechanism to an uncompetitive inhibitor of a single-substrate, single-product enzyme: a study of Helicobacter pylori glutamate racemase. FutureMedChem 5:1203-1214. http://dx.doi.org/10.4155/fmc.13.94.
25. Tuomanen EI, Cozens R, Tosch W, Zak O, Tomasz A. 1986. The rate of killing of Escherichia coli by β-lactam antibiotics is strictly proportional to the rate of bacterial growth. J Gen Microbiol 132:1297-1304.
26. van Zanten SJ, Kolesnikow T, Leung V, O'Rourke JL, Lee A. 2003. Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model. Antimicrob Agents Chemother 47:2249-2255. http://dx.doi.org/10.1128/AAC.47.7.2249-2255.2003.
27. Goddard AF. 1998. Getting to the route of Helicobacter pylori treatment. J Antimicrob Chemother 42:1-3. http://dx.doi.org/10.1093/jac/42.1.1.
28. Nielsen EI, Cars O, Friberg LE. 2011. Pharmacokinetic/pharmacodynamic (PK-PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrob Agents Chemother 55:4619-4630. http://dx.doi.org/10.1128/AAC.00182-11.
29. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89-96. http://dx.doi.org/10.1016/0732-8893(95)00053-D.
30. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12. http://dx.doi.org/10.1086/516284.
31. Craig WA, Andes D. 1996. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 15:255-259. http://dx.doi.org/10.1097/00006454-199603000-00015.
32. Salcedo JA, Al-Kawas F. 1998. Treatment of Helicobacter pylori infection. Arch Intern Med 158:842-851. http://dx.doi.org/10.1001/archinte.158.8.842.
33. Chesa-Jiménez J, Peris JE, Torres-Molina F, Granero L. 1994. Low bioavailability of amoxicillin in rats as a consequence of presystemic degradation in the intestine. Antimicrob Agents Chemother 38:842-847. http://dx.doi.org/10.1128/AAC.38.4.842.